Rethinking Age-Related Vision Loss [Sponsored]
Summary
Dr. Praveen Dugal, CEO of Ocular Therapeutics, explains wet age-related macular degeneration and the limitations of current anti-VEGF injections, which require frequent visits and cause retinal scarring. He introduces OTX-TKI, a hydrogel-encapsulated tyrosine kinase inhibitor designed to provide continuous drug release over nine to ten months. This innovation aims to reduce injection frequency to every six months while maintaining safety and efficacy. Dugal shares his personal motivation for developing this treatment, noting that his father and mother both suffered from wet AMD.
Topics discussed
Introduction to Age-Related Macular Degeneration (AMD)
Welcome and introduction of Dr. Praveen Dugal
How AMD affects vision: Dry vs. Wet mechanisms
Risk factors and progression from dry to wet AMD
Early warning signs and metamorphopsia
Historical context: The era before effective treatments
The role of VEGF and lessons from oncology
The evolution of anti-VEGF injections and initial expectations
Patient dropout rates and the burden of frequent injections
The patient experience: Logistics and adherence challenges
Long-term side effects: Retinal scarring from pulsatile treatment
Defining the ideal treatment profile for wet AMD
Introducing OTX-TKI: Hydrogel technology and FDA timeline
How the hydrogel works: Continuous drug elution
Personal connection: Dr. Dugal's family history with AMD
Closing remarks and sponsor disclosure
Listen ad-free on Castria